Rich Wing Email & Phone Number

Foster City, CA, US

• Team Leadership & Talent Cultivation:
• Leader of a team of 8 including 3 direct reports plus 5 dedicated vendor team members
• Candid leadership style that emphasizes transparency and accountability, effectively driving performance improvements and operational excellence
• Passion for mentorship: building agility, technical proficiency, and stakeholder management skillsStrategic Leadership & Collaboration:
• Deliver long-range plan including patient-based forecasting for ARC-10, EVOKE-03, PAC-8, STAR-121, STAR-131, and STAR-221
• Innovate novel scenario comparison analytics to inform robust decision making

Cambridge, Cambridgeshire, GB

• Spearhead commercial strategy on multiple early and late-stage product teams producing thorough and effective business cases for phase 3 investment
• Develop both early and late stage pan-tumor strategy across multiple assets: Imfinzi (PDL1), Enhertu (HER2 ADC), monalizumab (NKG2A), and PD-1 bispecifics: volrustomig (CTLA4), rilvegostomig (TIGIT), and sabestomig.
• Design and lead the development and launch of a cutting-edge digital infrastructure platform for a company-wide audience resulting in a transformational shift in idea exchange and decision-making

Powell, Ohio, US

• Managed and led teams of >3 juniors to deliver market research projects for biotech and pharma
• Evaluated early stage assets as well as launch benchmarking and patient journey projects
• Delivered projects across TAs: CVMD, neurology, oncology, rare disease, and respiratory
• Served as the key point of contact for repeat and new clients

New York, NEW YORK, US

• Led 3 direct reports and vendor teams of ~40 people to design Promontory’s valuation model, analyze clinical data, oversee process development, and ensure seamless drug supply chain
• Managed Promontory’s alliances with Pfizer, EMD Serono, and SciClone Pharmaceuticals
• Oversaw multiple departments as leader of research and operations team reporting to the COO

Bethesda, MD, US

• Led client presentations and served as a point of contact for clients
• Built risk-adjusted valuation models for clients in the pharmaceutical industry
• Produced market research projects on early stage (discovery through Phase 2) assets
• Covered oncology, autoimmune, CVRM, neurology, and rare disease spaces

New York, NY, US

• Led personnel to research the structural basis for transport across the nuclear envelope
• Partially funded research via award of NIH F32 grant
• Primary techniques included: cloning, heterologous protein expression, protein purification via FPLC, computational modeling, and X-ray crystallography

M.Phil, Ph.D., Molecular Biophysics And Biochemistry

A.B., Summa Cum Laude, Biochemistry

Certificate, Managing Science In The Biotech Industry